CHARACTERISTICS OF COGNITIVE STATUS OF EPILEPSY PATIENTS TREATED WITH MONOTHERAPY OF FIRST-GENERATION ANTIEPILEPTIC DRUGS
Keywords:epilepsy-associated cognitive decline, monotherapy, First-generation AEDs, MoCA-Ina score
Epilepsy is one of the main health problems in neurology that can lead to cognitive decline. Generally, the epilepsy-associated cognitive decline is influenced by demographic, clinical, and treatment characteristics. This study aimed to determine the characteristics of cognitive status of epilepsy patients who received monotherapy using first-generation antiepileptic drugs (AEDs), namely phenytoin, carbamazepine, and valproic acid. It involved 93 epilepsy patients of Mutiara Sukma Mental Hospital (n=38) and Mataram General Hospital (n=55). Besides, 93 healthy patients were assigned as healthy control group (HC) subjects (n=93). Demographic characteristics collected from epilepsy and HC groups were age, gender, and years of education. Clinical characteristics taken from both groups were MoCA-Ina score. Clinical characteristics taken from epilepsy group were age at epilepsy onset, type of seizure (partial vs generalized), etiology (idiopathic vs structural), first-generation AED used, years of treatment, and cognitive status. The result of the study revealed that there were no significant different between the two groups in the means of age and years of education as well as the frequency of male gender (p>0.05). The mean of MoCA-Ina score of epilepsy group was significantly lower compared with HC group (p<0.05). The frequency of cognitive decline among epilepsy patients was 75.3%. The cognitive functions of epilepsy patients using monotherapy with carbamazepine, phenytoin, or valproic acid was significantly lower compared with healthy subjects. We conclude that there was high prevalence of epilepsy-associated cognitive impairment which was associated with male gender.
Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon C-S, Dykeman J, et al. Prevalence and incidence of epilepsy A systematic review and meta-analysis of international studies. Neurology. 2017;88:296–303. Available from: doi: 10.1212/WNL.0000000000003509
Beghi E, Giussani G. Aging and the Epidemiology of Epilepsy. Neuroepidemiology. 2018;51:216–23. Available from: doi: 10.1159/000493484
Mac TL, Tran D, Quet F, Odermatt P, Preux P, Tan CT. Epidemiology, aetiology, and clinical management of epilepsy in Asia: a systematic review. Lancet Neurol. 2007;6:533–43. Available from: doi: 10.1016/S1474-4422(07)70127-8
Trinka E, Kwan P, Lee B, Dash A. Epilepsy in Asia: Disease burden, management barriers, and challenges. Epilepsia. 2019;60:7–21.
Nau A, Mwape K, Wiefek J, Schmidt K, Abatih E, Dorny P, et al. Cognitive impairment and quality of life of people with epilepsy and neurocysticercosis in Zambia. Epilepsy Behav. 2018;80:354–9. Available from: doi: 10.1016/j.yebeh.2017.10.042
Witt J, Helmstaedter C. Cognition in the early stages of adult epilepsy. Seizure. 2015;26:65–8. Available from: http://dx.doi.org/10.1016/j.seizure.2015.01.018
Witt J, Helmstaedter C. Should cognition be screened in new-onset epilepsies ? A study in 247 untreated patients. J Neurol. 2012;259:1727–31. Available from: DOI 10.1007/s00415-012-6526-2
Leeman-Markowski BA, Schachter SC. Cognitive and behavioral interventions in epilepsy. Curr Neurol Neurosci Rep. 2017;17(5):42.
Szemere E, Jokeit H. Quality of life is social – Towards an improvement of social abilities in patients with epilepsy. Seizure. 2015;26:12–21. Available from: http://dx.doi.org/10.1016/j.seizure.2014.12.008
Jost J, Millogo A, Preux P-M. Antiepileptic Treatments in Developing Countries. Curr Pharmacautical Des. 2017;23:1–9.
Lodhi S, Agrawal N. Neurocognitive problems in epilepsy. Adv Psychiatr Treat. 2012;18:232–40.
Salassie A, Wannamaker B, Smith G, Wagner J, Edwards J, Martz G, et al. Risk Factors of Epilepsy Outcomes: Comorbidities in Population with Epilepsy. South Carolina; 2014.
Lenck-Santini P-P, Scott RC. Mechanisms Responsible for Cognitive Impairment in Epilepsy. Cold Spring Harb Perspect Med. 2015;5:a022772.
Landi S, Petrucco L, Sicca F, Ratto GM. Transient Cognitive Impairment in Epilepsy. Front Mol Neurosci. 2019;11:458.
Witt J, Helmstaedter C. Monitoring the cognitive effects of antiepileptic pharmacotherapy — approaching the individual patient. Epilepsy Behav. 2013;26:450–6. Available from: http://dx.doi.org/10.1016/j.yebeh.2012.09.015
Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011;4(6):385–407. Available from: doi: 10.1177/%0A1756285611417920
Park S-P, Kwon S-H. Cognitive Effects of Antiepileptic Drugs. J Clin Neurol. 2008;4:99–106. Available from: 10.3988/jcn.2008.4.3.99
Budikayanti A, Qadri LM, Syeban Z, Indrawati LA, Octaviana F. Adverse Events of Antiepileptic Drugs Using Indonesian Version of Liverpool Adverse Events Profile. Neurol Res Int. 2018;2018:8490639. Available from: doi: 10.1016/S1474-4422(07)70127-8
Harahap H, Indrayana Y, Amalia E. Treatment Pattern and Cognitive Function in Epilepsy Patients in Mutiara Sukma Mental Hospital. J Kedokt Brawijaya. 2017;29(04):335–40. Available from: doi: http://dx.doi.org/10.21776/ub.jkb.2017.029.04.9
Loring DW, Marino S, Meador KJ. Neuropsychological and Behavioral Effects of Antiepilepsy Drugs. Neuropsychol Rev. 2007;17:413–25.
Wang L, Chen S, Liu C, Lin W, Huang H. Factors for cognitive impairment in adult epileptic patients. Brain Behav. 2020;10:e01475.
Wang Y-P, Gorenstein C. Assessment of depression in medical patients : A systematic review of the utility of the Beck Depression Inventory-II. Clinics. 2013;68(9):1274–87.
Crowe M, Clay OJ, Martin RC, Howard VJ, Wadley VG, Sawyer P, et al. Indicators of Childhood Quality of Education in Relation to Cognitive Function in Older Adulthood. J Gerontol A Biol Sci Med Sci. 2013;68(2):198–204.
Bicalho MAH, Sukys-Claudino L, Guarnieri R, Lin K, Walz R. Socio-demographic and clinical characteristics of Brazilian patients with epilepsy who drive and their association with traffic accidents. Epilepsy Behav. 2012;24(2):216–20. Available from: http://dx.doi.org/10.1016/j.yebeh.2012.04.114
Hixson JD. Stopping Antiepileptic Drugs: When and Why ? Curr Treat Options Neurol. 2010;12:434–42.
Husein N, Lumempouw S, Ramli Y, Herqutanto. Montreal Cognitive Assessment Versi Indonesia (MOCA-INA) Untuk Skrining Gangguan Fungsi Kognitif. Neurona. 2010;27(4):15–22.
Dumontheil I. Development of abstract thinking during childhood and adolescence: The role of rostrolateral prefrontal cortex. Dev Cogn Neurosci. 2014;10:57–76. Available from: http://dx.doi.org/10.1016/j.dcn.2014.07.009
Lorigados L, Orozco S, Morales L, Estupinan B, García I, Rocha L. Excitotoxicity and neuronal death in epilepsy. Biotecnol Apl. 2013;30:9–16.
Phabphal K, Kanjanasatien J. Montreal Cognitive Assessment in cryptogenic epilepsy patients with normal Mini-Mental State Examination. Epileptic Disord. 2011;13(4):375–81.
Mula M. Cognitive dysfunction in patients with epilepsy: focus on clinical variables. Future Neurol. 2015;10(1):41–8.
Banerjee PN, Filippi D, Hauser WA. The descriptive epidemiology of epilepsy-a review. Epilepsy Res. 2009;85(1):31–45.
Luine VN. Estradiol and cognitive function: Past, present and future. Horm Behav. 2014;66(4):602–18.
Rahman A, Jackson H, Hristov H, Isaacson RS, Saif N, Shetty T, et al. Sex and Gender Driven Modifiers of Alzheimer’s: The Role for Estrogenic Control Across Age, Race, Medical, and Lifestyle Risks. Front Aging Neurosci. 2019;11:315.
Gavrilovic A, Toncev G, Matic TB, Vesic K, Zivojinovic IJ, Gavrilovic J. Impact of epilepsy duration, seizure control and EEG abnormalities on cognitive impairment in drug-resistant epilepsy patients. Acta Neurol Belg. 2019;119(3):403–10. Available from: http://dx.doi.org/10.1007/s13760-019-01090-x
Witt J-A, Helmstaedter C. How can we overcome neuropsychological adverse effects of antiepileptic drugs? Expert Opin Pharmacother. 2017;18(6):551–4. Available from: http://dx.doi.org/10.1080/14656566.2017.1309025
Desai JD. Epilepsy and cognition. J Pediatr Neurosci. 2008;3:16–29.
Cameron A, Bansal A, Dua T, Hill SR, Moshe SL, Mantel-teeuwisse AK, et al. Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries. Epilepsia. 2012;53(6):962–9.